Prognostic significance of preoperative molecular serum analysis in renal cancer

Mark L. Gonzalgo, Claus F. Eisenberger, Shing M. Lee, Bruce J. Trock, Fray F. Marshall, Steven Hortopan, David Sidransky, Mark P. Schoenberg

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: We evaluated the postoperative clinical course of patients with renal cancer identified preoperatively by microsatellite analysis to examine the correlation between microsatellite alterations and risk of disease recurrence and patient mortality 2 years after nephrectomy. Experimental Design: A panel of 28 microsatellite markers was used previously to assess loss of heterozygosity and microsatellite instability in urine, serum, and tumor DNA of 30 patients with clinically organ-confined renal masses who underwent partial or radical nephrectomy. The clinical reports and imaging data in the medical records of patients with a minimum follow-up of 2 years were retrospectively reviewed to determine their postoperative course. Results: Two-year follow-up was available for the 30 patients (100%) who entered the study. Mean age was 61.6 ± 12.9 years (range, 21-77 years). Tumor stage was associated with patient mortality (P = 0.03). Tumor grade was associated with mortality (P = 0.03) and disease recurrence (P < 0.01). The frequency of microsatellite alterations (loss of heterozygosity) found in the preoperative serum of patients with renal masses served as a prognostic indicator for disease recurrence (P < 0.01). Conclusions: Analysis of microsatellite alterations found in preoperative blood samples is a promising method for the detection of renal cancer. The presence of frequent molecular changes in preoperative serum was associated with disease recurrence. These findings suggest a role for microsatellite analysis in future studies attempting to stratify patients with clinically organ-confined renal cancer into low- and high-risk prognostic groups. Larger prospective randomized trials are needed to validate the clinical utility of this observation.

Original languageEnglish (US)
Pages (from-to)1878-1881
Number of pages4
JournalClinical Cancer Research
Volume8
Issue number6
StatePublished - 2002
Externally publishedYes

Fingerprint

Kidney Neoplasms
Microsatellite Repeats
Serum
Recurrence
Loss of Heterozygosity
Nephrectomy
Mortality
Kidney
Neoplasms
Microsatellite Instability
Medical Records
Research Design
Urine
DNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gonzalgo, M. L., Eisenberger, C. F., Lee, S. M., Trock, B. J., Marshall, F. F., Hortopan, S., ... Schoenberg, M. P. (2002). Prognostic significance of preoperative molecular serum analysis in renal cancer. Clinical Cancer Research, 8(6), 1878-1881.

Prognostic significance of preoperative molecular serum analysis in renal cancer. / Gonzalgo, Mark L.; Eisenberger, Claus F.; Lee, Shing M.; Trock, Bruce J.; Marshall, Fray F.; Hortopan, Steven; Sidransky, David; Schoenberg, Mark P.

In: Clinical Cancer Research, Vol. 8, No. 6, 2002, p. 1878-1881.

Research output: Contribution to journalArticle

Gonzalgo, ML, Eisenberger, CF, Lee, SM, Trock, BJ, Marshall, FF, Hortopan, S, Sidransky, D & Schoenberg, MP 2002, 'Prognostic significance of preoperative molecular serum analysis in renal cancer', Clinical Cancer Research, vol. 8, no. 6, pp. 1878-1881.
Gonzalgo ML, Eisenberger CF, Lee SM, Trock BJ, Marshall FF, Hortopan S et al. Prognostic significance of preoperative molecular serum analysis in renal cancer. Clinical Cancer Research. 2002;8(6):1878-1881.
Gonzalgo, Mark L. ; Eisenberger, Claus F. ; Lee, Shing M. ; Trock, Bruce J. ; Marshall, Fray F. ; Hortopan, Steven ; Sidransky, David ; Schoenberg, Mark P. / Prognostic significance of preoperative molecular serum analysis in renal cancer. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 6. pp. 1878-1881.
@article{911d95f66c03486ea374b3461b5b3236,
title = "Prognostic significance of preoperative molecular serum analysis in renal cancer",
abstract = "Purpose: We evaluated the postoperative clinical course of patients with renal cancer identified preoperatively by microsatellite analysis to examine the correlation between microsatellite alterations and risk of disease recurrence and patient mortality 2 years after nephrectomy. Experimental Design: A panel of 28 microsatellite markers was used previously to assess loss of heterozygosity and microsatellite instability in urine, serum, and tumor DNA of 30 patients with clinically organ-confined renal masses who underwent partial or radical nephrectomy. The clinical reports and imaging data in the medical records of patients with a minimum follow-up of 2 years were retrospectively reviewed to determine their postoperative course. Results: Two-year follow-up was available for the 30 patients (100{\%}) who entered the study. Mean age was 61.6 ± 12.9 years (range, 21-77 years). Tumor stage was associated with patient mortality (P = 0.03). Tumor grade was associated with mortality (P = 0.03) and disease recurrence (P < 0.01). The frequency of microsatellite alterations (loss of heterozygosity) found in the preoperative serum of patients with renal masses served as a prognostic indicator for disease recurrence (P < 0.01). Conclusions: Analysis of microsatellite alterations found in preoperative blood samples is a promising method for the detection of renal cancer. The presence of frequent molecular changes in preoperative serum was associated with disease recurrence. These findings suggest a role for microsatellite analysis in future studies attempting to stratify patients with clinically organ-confined renal cancer into low- and high-risk prognostic groups. Larger prospective randomized trials are needed to validate the clinical utility of this observation.",
author = "Gonzalgo, {Mark L.} and Eisenberger, {Claus F.} and Lee, {Shing M.} and Trock, {Bruce J.} and Marshall, {Fray F.} and Steven Hortopan and David Sidransky and Schoenberg, {Mark P.}",
year = "2002",
language = "English (US)",
volume = "8",
pages = "1878--1881",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Prognostic significance of preoperative molecular serum analysis in renal cancer

AU - Gonzalgo, Mark L.

AU - Eisenberger, Claus F.

AU - Lee, Shing M.

AU - Trock, Bruce J.

AU - Marshall, Fray F.

AU - Hortopan, Steven

AU - Sidransky, David

AU - Schoenberg, Mark P.

PY - 2002

Y1 - 2002

N2 - Purpose: We evaluated the postoperative clinical course of patients with renal cancer identified preoperatively by microsatellite analysis to examine the correlation between microsatellite alterations and risk of disease recurrence and patient mortality 2 years after nephrectomy. Experimental Design: A panel of 28 microsatellite markers was used previously to assess loss of heterozygosity and microsatellite instability in urine, serum, and tumor DNA of 30 patients with clinically organ-confined renal masses who underwent partial or radical nephrectomy. The clinical reports and imaging data in the medical records of patients with a minimum follow-up of 2 years were retrospectively reviewed to determine their postoperative course. Results: Two-year follow-up was available for the 30 patients (100%) who entered the study. Mean age was 61.6 ± 12.9 years (range, 21-77 years). Tumor stage was associated with patient mortality (P = 0.03). Tumor grade was associated with mortality (P = 0.03) and disease recurrence (P < 0.01). The frequency of microsatellite alterations (loss of heterozygosity) found in the preoperative serum of patients with renal masses served as a prognostic indicator for disease recurrence (P < 0.01). Conclusions: Analysis of microsatellite alterations found in preoperative blood samples is a promising method for the detection of renal cancer. The presence of frequent molecular changes in preoperative serum was associated with disease recurrence. These findings suggest a role for microsatellite analysis in future studies attempting to stratify patients with clinically organ-confined renal cancer into low- and high-risk prognostic groups. Larger prospective randomized trials are needed to validate the clinical utility of this observation.

AB - Purpose: We evaluated the postoperative clinical course of patients with renal cancer identified preoperatively by microsatellite analysis to examine the correlation between microsatellite alterations and risk of disease recurrence and patient mortality 2 years after nephrectomy. Experimental Design: A panel of 28 microsatellite markers was used previously to assess loss of heterozygosity and microsatellite instability in urine, serum, and tumor DNA of 30 patients with clinically organ-confined renal masses who underwent partial or radical nephrectomy. The clinical reports and imaging data in the medical records of patients with a minimum follow-up of 2 years were retrospectively reviewed to determine their postoperative course. Results: Two-year follow-up was available for the 30 patients (100%) who entered the study. Mean age was 61.6 ± 12.9 years (range, 21-77 years). Tumor stage was associated with patient mortality (P = 0.03). Tumor grade was associated with mortality (P = 0.03) and disease recurrence (P < 0.01). The frequency of microsatellite alterations (loss of heterozygosity) found in the preoperative serum of patients with renal masses served as a prognostic indicator for disease recurrence (P < 0.01). Conclusions: Analysis of microsatellite alterations found in preoperative blood samples is a promising method for the detection of renal cancer. The presence of frequent molecular changes in preoperative serum was associated with disease recurrence. These findings suggest a role for microsatellite analysis in future studies attempting to stratify patients with clinically organ-confined renal cancer into low- and high-risk prognostic groups. Larger prospective randomized trials are needed to validate the clinical utility of this observation.

UR - http://www.scopus.com/inward/record.url?scp=0036281398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036281398&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 1878

EP - 1881

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -